ນັກວິເຄາະນັ່ງຢູ່ໃນຮົ້ວໃນຂະນະທີ່ລິເລີ່ມ Calliditas ໂດຍອ້າງເຖິງ 'ໂອກາດໃນໄລຍະຍາວແຕ່ຄໍາຖາມໄລຍະຍາວ'

• Guggenheim ການ​ຄຸ້ມ​ຄອງ​ລິ​ເລີ່ມ​ກ່ຽວ​ກັບ​ການ​ Calliditas Therapeutics AB (NASDAQ: CALT) with a Neutral rating and an $18 price target.

• The analyst is impressed with the data Tarpeyo has generated in Immunoglobulin A Nephropathy (IgAN) to date and the initial success the company has had with the commercial rollout of the product.

• While the analyst commends the Calliditas team for their progress with Tarpeyo in IgAN, including obtaining FDA Accelerated Approval and EU Conditional Approval, it notes mixed physician feedback, with some agreeing Tarpeyo’s delayed-release mechanism provides value over a traditional steroid but others wondering if that value is worth the added cost.

• Those doctors appear “more eager to use” endothelin receptor antagonists (ERAs) or more innovative approaches over time, added the analyst.

• FY22 Tarpeyo sales reached $36.8 million. The analyst expects continued progress with the launch and estimates peak 2028 U.S. Tarpeyo sales of ~$350 million before losing exclusivity in 2029.

• ລາຄາປະຕິບັດງານ: CALT shares are up 2.90% at $19.50 on the last check Wednesday.

Latest Ratings for CALT

ວັນທີ່ສະຫມັກ	ບໍລິສັດ	ການປະຕິບັດ	From	To
Dec 2021	HC Wainwright & Co.	ຮັກສາ		ຊື້
Jun 2020	ແຂງແຮງ	ລິເລີ່ມການຄຸ້ມຄອງໃນ		ຊື້
Jun 2020	Jefferies	ລິເລີ່ມການຄຸ້ມຄອງໃນ		ຊື້

View More Analyst Ratings for CALT

ເບິ່ງຄະແນນການວິເຄາະຫຼ້າສຸດ

ຢ່າພາດການແຈ້ງເຕືອນແບບສົດໆໃນຫຸ້ນຂອງເຈົ້າ – ເຂົ້າຮ່ວມ Benzinga Pro ສໍາລັບການຟຣີ! ລອງໃຊ້ເຄື່ອງມືທີ່ຈະຊ່ວຍໃຫ້ທ່ານລົງທຶນຢ່າງສະຫຼາດຂຶ້ນ, ໄວຂຶ້ນ, ແລະດີກວ່າ.

ຫົວ​ຂໍ້​ນີ້ ນັກວິເຄາະນັ່ງຢູ່ໃນຮົ້ວໃນຂະນະທີ່ລິເລີ່ມ Calliditas ໂດຍອ້າງເຖິງ 'ໂອກາດໃນໄລຍະຍາວແຕ່ຄໍາຖາມໄລຍະຍາວ' ປະກົດຢູ່ເບື້ອງຕົ້ນ benzinga.com

.

©ປີ 2023 Benzinga.com. Benzinga ບໍ່ໃຫ້ ຄຳ ແນະ ນຳ ດ້ານການລົງທືນ. ທິການ.